Results 191 to 200 of about 472,131 (258)

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer. [PDF]

Clin Pharmacokinet
Op 't Hoog CJP, Mehra N, van der Weij B, Olofsen E, Somford DM, van Oort IM, Hamberg P, van Erp NP, Boerrigter E.   +8 more
europepmc   +1 more source

Metal nanostructure‐coupled label‐free localized surface plasmon resonance biosensors for rapid and sensitive disease diagnosis

BMEMat, EarlyView.
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng, Yunfei Sha, Jiongyan Yang, Hongru Yang, Xiao Liang   +4 more
wiley   +1 more source

Pro-neuropeptide Y as a circulating biomarker for poor prognosis in prostate cancer. [PDF]

Sci Rep
Djusberg E, Lundquist K, Lundholm M, Josefsson A, Karlsson CT, Schwenk JM, Brattsand M, Bergh A, Wikström P.   +8 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Ozay ZI, Jo Y, Gebrael G, Ostrowski M, Mathew Thomas V, Li H, Graf RP, Roy S, Maughan BL, Guha A, Riaz IB, Antonarakis ES, McKay RR, Agarwal N, Swami U.   +14 more
europepmc   +1 more source

Modern proton therapy in prostate cancer: precision in practice. [PDF]

Front Oncol
Yacoub I, Khalil J, Wei S, Hsieh K, Chhabra AM, Mehta KJ, Oska C, Zhu L, Choi JI, Simone CB.   +9 more
europepmc   +1 more source

Prostatic cancer

Kidney International, 1993
openaire   +2 more sources

TMPRSS2-ERG confers resistance of prostate cancer to antiandrogens. [PDF]

EMBO Mol Med
Sekar A, Selvadurai BR, Chatterjee R, Pal L, Verma A, Belugali Nataraj N, Drago Garcia D, Giri S, Genna A, Karatekin F, Gupta N, Ramesh-Kumar D, Zerbib M, Vinik Y, Avioz T, Weizman E, David E, Schäffer AA, Pan Y, Huang H, van Weerden WM, Corey E, Hunt H, Greenstein AE, Blecher-Gonen R, Oren R, Afek A, Amit I, Lev S, Ku A, Kartal S, R Bright J, T Lis R, L Dahut W, Sowalsky AG, Ruppin E, Yarden Y.   +36 more
europepmc   +1 more source